Amicus Therapeutics will sell its gene therapy business to SPAC ARYA Sciences Acquisition Corp IV in exchange for 36% of its stock. ARYA will then change its name to Caritas Therapeutics and its stock will be listed on Nasdaq under the ticker symbol SPES. Amicus will retain the rights to jointly develop and commercialize Fabry and Pompe gene therapy programs, as well as the rights to negotiate certain future muscular dystrophy programs. The deal is expected to close in Q4 2021 or early 2022.